A New Drug For The Treatment Of Multiple Sclerosis

A New Drug For The Treatment Of Multiple Sclerosis.
An crackerjack consultive panel of the US Food and Drug Administration on Thursday recommended that the working approve an oral drug, Gilenia, as a first-line treatment for multiple sclerosis (MS) weight. Gilenia appears to be both suitable and effective, the panel confirmed in two separate votes.

Approval would earmark a major shift in MS therapy since other drugs for the neurodegenerative illness require frequent injections or intravenous infusions. "This is revolutionary," said Dr Janice Maldonado, an second professor of neurology at the University of Miami Miller School of Medicine al-shifa pharmacy product hair grow. "It's a marvelous attainment of being the before oral drug out for relapsing multiple sclerosis".

Maldonado, who has participated in trials with the drug, said the results have been very encouraging. "All of our patients have done well and have not had any problems, so it's positively promising". Patricia O'Looney, degeneracy president of biomedical research at the National Multiple Sclerosis Society, went even further, saying that "this is a signal day. The panel recommended the approval of Gilenia as a first-line option for persons with MS".